Benzinga | Oct 11, 2021 08:33AM EDT

JP Morgan Upgrades ChemoCentryx to Neutral, Raises Price Target to $38

JP Morgan analyst Anupam Rama upgrades ChemoCentryx (NASDAQ:CCXI) from Underweight to Neutral and raises the price target from $14 to $38.